Signify Bio

Signify Bio is a biotechnology firm focused on revolutionizing the development of in situ protein therapeutics. The company leverages the human body's natural ability to produce proteins, utilizing three proprietary platforms that encompass nucleic acid payloads and non-viral delivery systems. These platforms are designed to control the production, secretion, and localization of protein therapeutics directly within the human body. Signify Bio's core technology, the Signal peptide Engineered Nucleic acid Design (SEND) platform, allows precise control over the secretion and localization of any nucleic acid encodable protein. The company serves the biotechnology and pharmaceutical markets, targeting clients interested in personalized medicine solutions. Signify Bio operates on a business model that combines strategic partnerships and venture capital funding, generating revenue through the development and licensing of its proprietary platforms. The company recently secured $15 million in initial financing, with investments from notable entities such as the Actium Group, Gates Foundation Strategic Investment Fund, Danaher Ventures LLC, Eli Lilly and Company, and BrightEdge. This funding supports its mission to create personalized medicines accessible to all, positioning Signify Bio as a key player in the field of nucleic acid-enabled protein therapeutics.

Keywords: biotechnology, protein therapeutics, nucleic acid, mRNA design, peptide control, personalized medicine, non-viral delivery, SEND platform, venture capital, strategic partnerships.